BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2719 related articles for article (PubMed ID: 31968197)

  • 1. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 2. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on the correlation between type 2 diabetes mellitus combined with non-alcoholic steatohepatitis and aerobic exercise performance].
    Zhang J; Li L; Yu HY; Li Y; Wang FM; Di FS
    Zhonghua Gan Zang Bing Za Zhi; 2023 Oct; 31(10):1068-1074. PubMed ID: 38016772
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
    Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
    Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients.
    Bril F; Portillo-Sanchez P; Liu IC; Kalavalapalli S; Dayton K; Cusi K
    Diabetes Care; 2018 Jan; 41(1):187-192. PubMed ID: 29133343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2014 Oct; 100(5):. PubMed ID: 25303488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
    Lomonaco R; Bril F; Portillo-Sanchez P; Ortiz-Lopez C; Orsak B; Biernacki D; Lo M; Suman A; Weber MH; Cusi K
    Diabetes Care; 2016 Apr; 39(4):632-8. PubMed ID: 26861926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.
    Pais R; Charlotte F; Fedchuk L; Bedossa P; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2013 Sep; 59(3):550-6. PubMed ID: 23665288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 136.